Skip to content

Advocacy at the World Health Organization

WHF is the only CVD organization in official relations with the WHO. Advocating directly to the WHO for improved CVD prevention and control.

Strategically located in Geneva, the seat of the World Health Organization (WHO), WHF advocates at the highest levels to bring CVD to the forefront of the global health agenda. We work with representatives of Member States and key decision-makers at the WHO in a number of ways:

  • Attending and advocating at global and regional meetings organized by WHO
  • Aligning our workplan and objectives with the WHO goal of achieving a 25% reduction in premature mortality from NCDs by the year 2025 and UN SDG 3.4 on reducing by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being by 2030.
  • Working with key teams within the WHO to develop and implement health tools and policy
  • Supporting the WHO Global Coordinating Mechanism
  • Responding to consultations on CVD-related health topics
  • Engaging with and supporting Member States as they work to achieve UHC

The World Heart Federation Advocacy Team represents the policy interests of our Members at major regional and global health conferences to advocate for improved CVD prevention and control.

The Executive Board (EB) meetings of the WHO are held twice annually, in January/February and May/June. During these meetings, Member States debate pressing global health issues and propose draft resolutions to tackle these problems, which are then submitted for consideration and adoption at the World Health Assembly.

The World Health Assembly (WHA) is the main decision-making and governance body of the WHO, where Member States debate and decide on key global health issues. Taking place in Geneva once a year, its agenda is largely determined by the WHO Executive Board meetings.

The WHO Regional Committee Meetings offer additional key advocacy opportunities. Held annually from August to October, these meetings address pressing health issues specific to each of the six WHO Regions.

At each of these meetings, the WHF Advocacy Team takes the opportunity to make statements on Agenda Items relevant to CVD and NCDs, as well as related topics, such as access to essential medicines and the health of refugees and migrants.

The WHO Executive Board, World Health Assembly and WHO Regional Committee Meetings also gather important health actors and decision-makers together, presenting valuable opportunities to advocate for improved CVD prevention and control at a targeted scale.

Providing a roadmap and policy options to achieve the global 25 by 25 targets

To accelerate the UN’s commitments to address NCDs in 2011, the World Health Organization created a Global Action Plan for the Prevention and Control of NCDs, which covers the years 2013-2020. This document was written in collaboration with the World Heart Federation and other health stakeholders and provides countries with a plan of action and menu of policy options to reduce their burden of CVD.

The Global Action Plan (GAP) recognizes that governments have a primary role and responsibility to play in responding to the challenge of NCDs, but require the support of international organizations and other experts. It is structured around a WHO goal of achieving a 25% reduction in premature mortality from NCDs by the year 2025. From this broad NCD goal, the World Heart Federation set its own ambitious global goal of reducing premature death from CVD by 25% by 2025.

Providing a framework to track progress towards the global 25 by 25 targets

To support the Global Action Plan, the WHO created the NCD Global Monitoring Framework (GMF) to track progress in preventing and controlling the four major NCDs. The GMF tracks progress on NCDs against the nine voluntary global targets highlighted in the GAP, so is a key tool to hold countries accountable to their UN commitments. The framework is also intended to provide the foundation for advocacy, raising awareness, reinforcing political commitment and promoting global action.

Created in 2014, the WHO Global Coordination Mechanism on NCDs (GCM) was established to support the implementation of the Global Action Plan (GAP) and Global Monitoring Framework (GMF) by coordinating activities, engagement and cross-sector action. Led by Member States, other participants include United Nations organizations, non-governmental organizations and academic institutions.

The World Heart Federation has participated actively in the GAP, GMF and GCM since their inception, both independently and through the NCD Alliance.

WHF is the only CVD organization in official relations with the WHO. This special status not only allows us to make statements representing the interests of our Members at meetings of the governing bodies, but also necessitates a formal shared workplan and close working relationship with the Department for Universal Health Coverage/Communicable and Noncommunicable Diseases.

WHF currently supports the WHO in its promotion of the HEARTS technical package, development of capacity-building materials related to air pollution and CVD, and implementation of the 2018 WHA Resolution on RHD, among other areas of work.

Latest News

World Heart Grants 2024 are open!

We are delighted to open applications for a new round of World Heart Grants, available exclusively to WHF Members. The World Heart Grants support our Members’ efforts to raise awareness of heart health and reduce the burden and impact of cardiovascular disease in their communities. We are looking for projects that reflect our mission to connect and […]

One to watch: An urgent call for early detection of rheumatic heart disease and more equitable cardiovascular care

Access to imaging technologies allows for early screening and intervention, positively impacting outcomes for patients with heart diseases. An urgent call for early screening in Rheumatic Heart Disease is a new film by the World Heart Federation and Philips Foundation. By telling the story of David, a young man from the Philippines who has been […]

It is time to screen for homozygous familial hypercholesterolemia in the United States

The World Heart Federation is excited to celebrate the first-ever HoFH Awareness Day with the international FH and HoFH communities on 4 May 2024. Homozygous Familial Hypercholesterolemia (HoFH) is an ultra-rare inherited condition characterized by extremely high and life-threatening levels of low-density lipoprotein (LDL) cholesterol from birth, leading to significant premature cardiovascular morbidity and mortality. […]

WHF partners with Clean Air Fund to combat air pollution’s impact on heart health

In 2023 the World Heart Federation was proud to begin engagement in a new series of activities in partnership with the Clean Air Fund (CAF) through their Health Grant programme. CAF is providing support for WHF to engage in research and advocacy on air pollution (AP) and CVD across a two-year implementation period. The global […]